HGH Fragment 176-191 5mg – fat burning

What is HGH Fragment 176-191? 

This peptide has been studied as a molecule that can direct the body to use stored fat for energy and limit the accumulation of new fat, without targeting the classical effects of growth hormone on height and tissue growth.

HGH Fragment 176-191 represents a 16-amino-acid sequence derived from hGH, and is used primarily as a tool for mechanistic studies of metabolic endpoints, rather than as a substitute for hGH in endocrinology (review: Wikipedia: HGH Frag 176-191; general context for GH axis and signaling: NCBI Bookshelf).

Mechanism of action

Data from the literature describe a functional "dissociation" of effects: the fragment is studied for potential stimulation of lipolysis and suppression of de novo lipogenesis in adipose tissue, with discussions of interactions with receptor/post-receptor nodes of GH signaling and secondary mediators. For laboratory interpretation it is important that the mechanistic link with the GH receptor and the role of IGF‑1 remain context-dependent and are often assessed through panels of markers (FFA, glycerol release, expression of lipogenic enzymes) (general principles for peptide pharmacology and signaling: NCBI Bookshelf).

In scientific/laboratory settings it is applied for in vitro tests (adipocytes, hepatocytes), ex vivo tissue models and in vivo protocols in animals, focusing on metabolic endpoints and comparison against hGH or control peptides. Pharmacokinetics in humans are not standardized in public regulatory documents; in planning, pilot time‑course schemes are used (sampling for plasma stability/decay, LC‑MS) and assessment of protease stability.

Purity and specification (MyPeptid)

HGH Fragment 176‑191 на MyPeptid provides suitable conditions for reproducible assays, as it has a purity above 99% (HPLC) and is intended for analytical traceability in R&D workflows.

Formula: C78H125N23O24

For sale for educational and research purposes only (research-only), not for clinical use.